Answers are grounded in this paper and cite their sources.
Impaired wound healing is an enigmatic and debilitating complication of diabetes. A consensus as to the pathogenesis of this disorder has yet to emerge. Recent concepts suggest that IGF-1 is an important regulator of the healing process. The level of this growth factor is reduced in the wound environment of diabetics. We tested the premise that IGF-1 administration may prevent or ameliorate wound healing impairment in streptozotocin (STZ, 55 mg/kg, iv) diabetic rats. IGF-1 (15 micrograms/day) or placebo was infused via mini-osmotic pumps into standardized stainless steel dorsal wound chambers. Wound-related parameters including protein, DNA, hydroxyproline and macrophages were decreased as a function of diabetes. A 14-day treatment with IGF-1 reversed the diabetes effect and increased total hydroxyproline, DNA, protein and macrophage numbers by 48%, 52%, 31% and 40% above vehicle-control values, respectively. The data support the premise that diabetes, related suppression of IGF-1 and/or macrophage function within the wound environment is responsible, at least in part, for the wound healing impairment in this disease state.
No takes yet. Share an insight, caveat, or question.
Milad S. Bitar (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: